RIGI and neoplasm: A potent benefit of therapeutic activation of RIG-I was described recently in different indications: i) 3pRNA suppresses tumor growth by triggering apoptosis specifically in tumor but not in non-malignant cells as well as by inducing an anti-tumor immune response, including type I IFN induction and NK cell activation [7–10].